Eurotimes Articles

MARKETING AUTHORISATION

Posted in:

Santen Pharmaceutical has announced that the European Medicines Agency (EMA) has accepted the company’s Marketing Authorisation Application (MAA) filing for the use of intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of noninfectious uveitis (NIU) of the posterior segment.
“Given the risks associated with currently available therapeutic options for NIU of the posterior segment, a chronic inflammatory condition in many cases, there is a significant need for novel treatments that could be used,” says Dr Naveed Shams, Chief Scientific Officer and Head, Global R&D, Santen Ltd.
www.santeninc.com

Back to Previous

Popular Items